Clinical trial · Interventional
Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma
NCT06916416CI-TRIAL-00088288PREFernot yet recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
By the implementation of the anti-PD-1 antibody pembrolizumab and given its possible synergy with RT, the aim of the present trial is to develop a chemotherapy-free first-line treatment for patients with newly diagnosed early-stage favorable cHL.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Classical Hodgkin Lymphoma | Classic Hodgkin Lymphoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pembrolizumab | Drug | Pembrolizumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Pembrolizumab
- description
- All patients will receive 6 doses of 200mg Pembrolizumab iv as single agent every three weeks followed by 20Gy radiotherapy
- interventionNames
- Drug: Pembrolizumab
Primary outcomes (1)
- measure
- Progression Free Survival
- timeFrame
- PFS at 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven first diagnosis of cHL * Stage I-II without risk factors * Large mediastinal mass * Extranodal involvement * Elevated erythrocyte sedimentation rate (ESR) * Involvement of ≥ 3 nodal areas Exclusion Criteria: * Central nervous system lymphoma, nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma, * Prior cHL-directed treatment * Prior chemotherapy, RT or allogeneic stem cell/solid organ transplant * Prior or concurrent disease precluding protocol treatment (for details see section 4.2) * Pregnancy or breastfeeding * Non-compliance
References
Publications (0)
Data not yet available
No reference posted for this study.